Advanced Pathophysiology HESI Final Examination 2025/2026 –
Graduate Nursing Program – Comprehensive Disease
Mechanism & Clinical Correlation Competency Assessment —
100 Questions and Answers Already Graded A+ Premium Exam
Tested And Verified
Subject Area Advanced Pathophysiology
Description This comprehensive examination assesses mastery of advanced
pathophysiological mechanisms underlying major diseases, with emphasis on
molecular, cellular, and systemic alterations, and their clinical correlations.
Content spans genetic disorders, immunological dysfunction, oncogenesis,
cardiovascular and respiratory pathophysiology, renal and endocrine disruptions,
neurobiology, and multisystem failure. The exam integrates current
evidence-based knowledge and prepares graduate nursing professionals for
clinical decision-making and research application.
Expected Grade A+
Total Questions 100
Duration 3 hours
Learning Outcomes 1. Analyze the molecular and cellular mechanisms of disease initiation and
progression.
2. Integrate pathophysiological concepts across organ systems to explain complex
clinical presentations.
3. Evaluate the impact of genetic and epigenetic factors on disease susceptibility
and treatment response.
4. Apply current pathophysiological knowledge to anticipate complications and
guide therapeutic interventions.
Accreditation This examination adheres to the rigorous standards of the Commission on
Collegiate Nursing Education (CCNE) and the American Association of Colleges
of Nursing (AACN) Essentials for Doctoral Nursing Education.
Page 1
,1. A research study investigates a novel tumor suppressor gene that encodes a
protein responsible for ubiquitinating and degrading a key transcription factor that
promotes cell cycle progression. Loss of function of this gene is found in a subset of
aggressive breast cancers. Which of the following best describes the mechanism by
which this gene normally suppresses tumor formation?
A. It directly inhibits cyclin-dependent kinase activity by binding to the kinase active site.
B. It promotes the proteasomal degradation of a proto-oncogene product, thereby reducing its
cellular levels.
C. It acts as a transcription factor that upregulates pro-apoptotic genes in response to DNA
damage.
D. It stabilizes p53 by preventing its interaction with MDM2.
Answer: B. It promotes the proteasomal degradation of a proto-oncogene product,
thereby reducing its cellular levels.
The gene encodes an E3 ubiquitin ligase that targets a proto-oncogene transcription
factor for proteasomal degradation, thereby reducing its proliferative signaling. This is
a classic tumor suppressor mechanism distinct from direct CDK inhibition (A), p53
stabilization (D), or transcriptional activation of apoptosis (C).
2. A patient presents with severe hypertension, hypokalemia, and metabolic
alkalosis. Laboratory findings show low plasma renin activity and elevated
aldosterone levels. Further testing reveals a mutation in the gene encoding the
potassium channel KCNJ5. Which of the following best explains the pathophysiology
of this patient's condition?
A. The mutation causes constitutive activation of the aldosterone synthase enzyme, leading
to excessive aldosterone production independent of angiotensin II.
B. The mutation results in a gain of function in the potassium channel, causing zona
glomerulosa cell depolarization and increased aldosterone secretion.
C. The mutation leads to loss of function of the potassium channel, causing
hyperpolarization and reduced aldosterone secretion.
D. The mutation impairs the degradation of aldosterone in the liver, resulting in elevated
circulating levels.
Answer: B. The mutation results in a gain of function in the potassium channel,
causing zona glomerulosa cell depolarization and increased aldosterone secretion.
Gain-of-function mutations in KCNJ5 (encoding Kir3.4) cause increased sodium
conductance and cell depolarization in adrenal zona glomerulosa cells, activating
voltage-gated calcium channels and increasing aldosterone production. This leads to
primary aldosteronism with low renin, hypertension, hypokalemia, and metabolic
alkalosis.
Page 2
,3. A 45-year-old individual with a history of recurrent sinopulmonary infections,
autoimmune thrombocytopenia, and splenomegaly is found to have a low level of
CD27+ memory B cells and impaired antibody responses to polysaccharide vaccines.
Genetic analysis reveals a mutation in the gene encoding CD40 ligand. Which of the
following laboratory findings would most likely be present in this individual?
A. Elevated serum IgM with low IgG, IgA, and IgE
B. Low serum IgM, IgG, IgA, and IgE
C. Elevated serum IgG and IgA with low IgM
D. Normal immunoglobulin levels but absent specific antibody production
Answer: A. Elevated serum IgM with low IgG, IgA, and IgE
CD40 ligand deficiency (X-linked hyper-IgM syndrome) impairs class switch
recombination and somatic hypermutation in B cells. Patients have normal or elevated
IgM but low IgG, IgA, and IgE, due to inability to switch from IgM to other isotypes.
They also have defective germinal center formation, leading to low memory B cells and
poor antibody responses.
4. In a patient with chronic kidney disease (stage 4), which of the following best
describes the compensatory adaptation in the remaining functional nephrons that
helps maintain glomerular filtration rate (GFR) despite significant nephron loss?
A. Afferent arteriolar constriction mediated by increased angiotensin II to raise filtration
pressure.
B. Increased single-nephron GFR due to afferent arteriolar dilation and increased glomerular
capillary pressure.
C. Tubuloglomerular feedback activation that increases sodium delivery to the macula densa,
promoting afferent vasodilation.
D. Decreased production of vasodilatory prostaglandins in the juxtaglomerular apparatus.
Answer: B. Increased single-nephron GFR due to afferent arteriolar dilation and
increased glomerular capillary pressure.
In chronic kidney disease, compensatory hyperfiltration occurs in remaining nephrons
via afferent arteriolar dilation (mediated by factors like nitric oxide and
prostaglandins) and increased glomerular capillary pressure, raising single-nephron
GFR. This adaptation initially preserves total GFR but eventually leads to glomerular
sclerosis and further nephron loss.
Page 3
, 5. A patient with a history of recurrent deep vein thrombosis presents with
unexplained pulmonary embolism. Coagulation studies show normal prothrombin
time, normal activated partial thromboplastin time, and elevated plasma levels of
D-dimer. Further testing reveals a mutation in the 3'-untranslated region of the
prothrombin gene. Which of the following best describes the molecular consequence
of this mutation?
A. Increased synthesis of a dysfunctional prothrombin protein with reduced activity.
B. Increased mRNA stability leading to elevated prothrombin levels in plasma.
C. Impaired cleavage of prothrombin to thrombin by factor Xa.
D. Reduced binding of prothrombin to phospholipid surfaces on platelets.
Answer: B. Increased mRNA stability leading to elevated prothrombin levels in
plasma.
The prothrombin G20210A mutation is a gain-of-function polymorphism in the 3'-UTR
that increases prothrombin mRNA stability and translation efficiency, resulting in
higher plasma prothrombin levels. This enhances thrombin generation and increases
the risk of venous thromboembolism, without affecting the protein's function or
cleavage.
Page 4
Graduate Nursing Program – Comprehensive Disease
Mechanism & Clinical Correlation Competency Assessment —
100 Questions and Answers Already Graded A+ Premium Exam
Tested And Verified
Subject Area Advanced Pathophysiology
Description This comprehensive examination assesses mastery of advanced
pathophysiological mechanisms underlying major diseases, with emphasis on
molecular, cellular, and systemic alterations, and their clinical correlations.
Content spans genetic disorders, immunological dysfunction, oncogenesis,
cardiovascular and respiratory pathophysiology, renal and endocrine disruptions,
neurobiology, and multisystem failure. The exam integrates current
evidence-based knowledge and prepares graduate nursing professionals for
clinical decision-making and research application.
Expected Grade A+
Total Questions 100
Duration 3 hours
Learning Outcomes 1. Analyze the molecular and cellular mechanisms of disease initiation and
progression.
2. Integrate pathophysiological concepts across organ systems to explain complex
clinical presentations.
3. Evaluate the impact of genetic and epigenetic factors on disease susceptibility
and treatment response.
4. Apply current pathophysiological knowledge to anticipate complications and
guide therapeutic interventions.
Accreditation This examination adheres to the rigorous standards of the Commission on
Collegiate Nursing Education (CCNE) and the American Association of Colleges
of Nursing (AACN) Essentials for Doctoral Nursing Education.
Page 1
,1. A research study investigates a novel tumor suppressor gene that encodes a
protein responsible for ubiquitinating and degrading a key transcription factor that
promotes cell cycle progression. Loss of function of this gene is found in a subset of
aggressive breast cancers. Which of the following best describes the mechanism by
which this gene normally suppresses tumor formation?
A. It directly inhibits cyclin-dependent kinase activity by binding to the kinase active site.
B. It promotes the proteasomal degradation of a proto-oncogene product, thereby reducing its
cellular levels.
C. It acts as a transcription factor that upregulates pro-apoptotic genes in response to DNA
damage.
D. It stabilizes p53 by preventing its interaction with MDM2.
Answer: B. It promotes the proteasomal degradation of a proto-oncogene product,
thereby reducing its cellular levels.
The gene encodes an E3 ubiquitin ligase that targets a proto-oncogene transcription
factor for proteasomal degradation, thereby reducing its proliferative signaling. This is
a classic tumor suppressor mechanism distinct from direct CDK inhibition (A), p53
stabilization (D), or transcriptional activation of apoptosis (C).
2. A patient presents with severe hypertension, hypokalemia, and metabolic
alkalosis. Laboratory findings show low plasma renin activity and elevated
aldosterone levels. Further testing reveals a mutation in the gene encoding the
potassium channel KCNJ5. Which of the following best explains the pathophysiology
of this patient's condition?
A. The mutation causes constitutive activation of the aldosterone synthase enzyme, leading
to excessive aldosterone production independent of angiotensin II.
B. The mutation results in a gain of function in the potassium channel, causing zona
glomerulosa cell depolarization and increased aldosterone secretion.
C. The mutation leads to loss of function of the potassium channel, causing
hyperpolarization and reduced aldosterone secretion.
D. The mutation impairs the degradation of aldosterone in the liver, resulting in elevated
circulating levels.
Answer: B. The mutation results in a gain of function in the potassium channel,
causing zona glomerulosa cell depolarization and increased aldosterone secretion.
Gain-of-function mutations in KCNJ5 (encoding Kir3.4) cause increased sodium
conductance and cell depolarization in adrenal zona glomerulosa cells, activating
voltage-gated calcium channels and increasing aldosterone production. This leads to
primary aldosteronism with low renin, hypertension, hypokalemia, and metabolic
alkalosis.
Page 2
,3. A 45-year-old individual with a history of recurrent sinopulmonary infections,
autoimmune thrombocytopenia, and splenomegaly is found to have a low level of
CD27+ memory B cells and impaired antibody responses to polysaccharide vaccines.
Genetic analysis reveals a mutation in the gene encoding CD40 ligand. Which of the
following laboratory findings would most likely be present in this individual?
A. Elevated serum IgM with low IgG, IgA, and IgE
B. Low serum IgM, IgG, IgA, and IgE
C. Elevated serum IgG and IgA with low IgM
D. Normal immunoglobulin levels but absent specific antibody production
Answer: A. Elevated serum IgM with low IgG, IgA, and IgE
CD40 ligand deficiency (X-linked hyper-IgM syndrome) impairs class switch
recombination and somatic hypermutation in B cells. Patients have normal or elevated
IgM but low IgG, IgA, and IgE, due to inability to switch from IgM to other isotypes.
They also have defective germinal center formation, leading to low memory B cells and
poor antibody responses.
4. In a patient with chronic kidney disease (stage 4), which of the following best
describes the compensatory adaptation in the remaining functional nephrons that
helps maintain glomerular filtration rate (GFR) despite significant nephron loss?
A. Afferent arteriolar constriction mediated by increased angiotensin II to raise filtration
pressure.
B. Increased single-nephron GFR due to afferent arteriolar dilation and increased glomerular
capillary pressure.
C. Tubuloglomerular feedback activation that increases sodium delivery to the macula densa,
promoting afferent vasodilation.
D. Decreased production of vasodilatory prostaglandins in the juxtaglomerular apparatus.
Answer: B. Increased single-nephron GFR due to afferent arteriolar dilation and
increased glomerular capillary pressure.
In chronic kidney disease, compensatory hyperfiltration occurs in remaining nephrons
via afferent arteriolar dilation (mediated by factors like nitric oxide and
prostaglandins) and increased glomerular capillary pressure, raising single-nephron
GFR. This adaptation initially preserves total GFR but eventually leads to glomerular
sclerosis and further nephron loss.
Page 3
, 5. A patient with a history of recurrent deep vein thrombosis presents with
unexplained pulmonary embolism. Coagulation studies show normal prothrombin
time, normal activated partial thromboplastin time, and elevated plasma levels of
D-dimer. Further testing reveals a mutation in the 3'-untranslated region of the
prothrombin gene. Which of the following best describes the molecular consequence
of this mutation?
A. Increased synthesis of a dysfunctional prothrombin protein with reduced activity.
B. Increased mRNA stability leading to elevated prothrombin levels in plasma.
C. Impaired cleavage of prothrombin to thrombin by factor Xa.
D. Reduced binding of prothrombin to phospholipid surfaces on platelets.
Answer: B. Increased mRNA stability leading to elevated prothrombin levels in
plasma.
The prothrombin G20210A mutation is a gain-of-function polymorphism in the 3'-UTR
that increases prothrombin mRNA stability and translation efficiency, resulting in
higher plasma prothrombin levels. This enhances thrombin generation and increases
the risk of venous thromboembolism, without affecting the protein's function or
cleavage.
Page 4
